Analysis of the DM-ILD group indicated positivity for the anti-MDA5 antibody in 70 patients (72.2%), for the anti-NXP2 antibody in two patients (2.1%), for the anti-Mi-2 antibody in five patients (5.2%), for the anti-TIF-1γ antibody in four patients (4.1%), and for the anti-SAE antibody in one patient (1.0%). Here, TRIM33 is linked to dermatomyositis.